Results 41 to 50 of about 126,141 (353)

A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies [PDF]

open access: yes, 2020
With recent advancements in the understanding of vitiligo pathogenesis, Janus kinase (JAK) inhibitors have emerged as a promising new treatment modality, but their effects remain incompletely elucidated.
Alikhan, Mujahed   +4 more
core  

Overcoming steroid resistance in T cell acute lymphoblastic leukemia [PDF]

open access: yes, 2016
In a Perspective, Pieter Van Vlierberghe and Steven Goossens discuss Meijerink and colleagues' findings on steroid resistance in pediatric T cell acute lymphoblastic ...
Goossens, Steven   +1 more
core   +3 more sources

Intracellular mechanisms underlying the nicotinic enhancement of LTP in the rat dentate gyrus [PDF]

open access: yes, 2008
We have previously shown that activation of nicotinic acetylcholine receptors (nAChRs) enhanced long-term potentiation (LTP) in the rat dentate gyrus in vitro via activation of α7 nAChR. In the present studies, mechanisms underlying the acute and chronic
Abel   +81 more
core   +1 more source

JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases

open access: yesFrontiers in Medicine, 2023
Inflammatory bowel disease (IBD) is a chronic immune-mediated condition of the gastrointestinal tract that requires chronic treatment and strict surveillance.
Claudia Herrera-deGuise   +3 more
doaj   +1 more source

Therapeutic role of JAK inhibitors in hepatogastrointestinal diseases [PDF]

open access: yesExploration of Digestive Diseases
Janus kinase (JAK) inhibitors represent a major advancement in the management of immune-mediated inflammatory diseases. A balanced approach that carefully weighs therapeutic benefits against potential risks is essential.
Maged Tharwat Elghannam   +6 more
doaj   +1 more source

The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies

open access: yesFrontiers in Pharmacology, 2022
Background: Due to the lack of comprehensive evidence based on prospective studies, the efficacy and safety of Janus Kinase (JAK) inhibitors (including tofacitinib, ruxolitinib, baricitinib, ritlecitinib and brepocitinib) for alopecia areata (AA) are yet
Diqin Yan   +16 more
doaj   +1 more source

PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy [PDF]

open access: yes, 2017
Pancreatic ductal adenocarcinoma (PDAC) is considered a non‐immunogenic tumor, and immune checkpoint inhibitor monotherapy lacks efficacy in this disease. Radiotherapy (RT) can stimulate the immune system.
Azad, Abul   +11 more
core   +1 more source

New targets for resolution of airway remodeling in obstructive lung diseases. [PDF]

open access: yes, 2018
Airway remodeling (AR) is a progressive pathological feature of the obstructive lung diseases, including asthma and chronic obstructive pulmonary disease (COPD).
Deshpande, Deepak A.   +2 more
core   +2 more sources

Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing [PDF]

open access: yes, 2020
Both inflammatory diseases like rheumatoid arthritis (RA) and anti-inflammatory treatment of RA with glucocorticoids (GCs) or non-steroidal anti-inflammatory drugs (NSAIDs) negatively influence bone metabolism and fracture healing.
Brinkman, Antonia Clara Katharina   +10 more
core   +1 more source

Systemic Problems: A perspective on stem cell aging and rejuvenation. [PDF]

open access: yes, 2015
This review provides balanced analysis of the advances in systemic regulation of young and old tissue stem cells and suggests strategies for accelerating development of therapies to broadly combat age-related tissue degenerative pathologies.
CONBOY, Irina M   +2 more
core   +2 more sources

Home - About - Disclaimer - Privacy